Product
⁸⁹Zr-Df-IAB22M2C
1 clinical trial
2 indications
Indication
Positron Emission TomographyIndication
Metastatic Solid TumorsClinical trial
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in CombinationStatus: Completed, Estimated PCD: 2021-10-19